Ruso Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.00 M
- Company Age 3 Year,
- Last Filing with ROC 31 Mar 2024
About Ruso Pharma
Ruso Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 February 2022 (Three years 0 days old ). Its registered office is in Navimumbai, Maharashtra.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sanket Varal, Ritik Jain, Khandu Varal, and One other member serve as directors at the Company.
Company Details
- Location Navimumbai, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239MH2022PTC377317
- Company No.
377317
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Feb 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ruso Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanket Varal  | Director | 05-Mar-2022 | Current |
| Ritik Jain | Director | 05-Mar-2022 | Current |
| Khandu Varal | Director | 22-Feb-2022 | Current |
| Vasant Jain | Director | 22-Feb-2022 | Current |
Financial Performance of Ruso Pharma.
Enhance accessibility to Ruso Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Ruso Pharma?
Unlock access to Ruso Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Topnotch Chemicals Pvt LtdKhandu Varal and Vasant Jain are mutual person
Calyx Chemicals And Pharmaceuticals LimitedSanket Varal, Ritik Jain and 2 more are mutual person
Amret Life Science Private LimitedKhandu Varal and Vasant Jain are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ruso Pharma?
Ruso Pharma has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ruso Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ruso Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.